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An extensive workup is generally performed before allogeneic transplantation. The extent of this workup varies
substantially between centers because of a lack of guidelines.We analyzed 157 consecutive allogeneic transplant
candidates to understand the signiﬁcance of components of the pretransplant evaluation. Workup consisted of
chest computed tomography (CT); magnetic resonance imaging of the head; dental, ears-nose-throat (ENT),
ophthalmology, and gynecology evaluations; pulmonary function tests; echocardiography; cytomegalovirus
PCR; urine culture; clinical evaluation; and disease staging. Results were categorized as “normal or minor
ﬁnding” or “major ﬁnding” (having signiﬁcant consequences such as further testing or therapy). Major ﬁndings
were classiﬁed as incidental or related to history and symptoms. Components of the pretransplant workup with
the highest rate ofmajorﬁndingswere CT (22%), dental evaluation (13%), and ENT (12%,mostly symptomatic). All
other components had a low rate of major ﬁndings. Although 126 transplants were performed as scheduled, 24
were delayed and 7 canceled at short notice. The main reasons for delaying or canceling transplantation were
active infection and unexpected disease progression. A prospective evaluation of a more restricted, symptom-
guided pretransplant evaluation appears to be warranted.
 2014 American Society for Blood and Marrow Transplantation.Study Design and DeﬁnitionsINTRODUCTION
Allogeneic hematopoietic stem cell transplantation
(HSCT) is standard of care for a number of hematologic dis-
eases. The procedure is associated with a substantial risk of
morbidity and mortality. Efforts to make transplantation
safer include an optimal selection of transplant candidates
and an extensive pretransplant workup. The aims of this
workup are to ensure sufﬁcient organ function, rule out in-
fections, evaluate disease status, and generally exclude any
contraindications to allogeneic transplantation. Although
recommendations concerning the pretransplant evaluation
have been published [1], the extent and logistics of the pre-
transplant workup vary substantially among centers.
Numerous studies have shown a correlation between
pretransplant abnormalities and transplant outcome, either
for individual parameters such as pulmonary function tests
[2] and echocardiography [3] or in the form of comorbidity
scores, such as the hematopoietic cell transplantation-
speciﬁc comorbidity index [4]. However, only a few studies
have analyzed whether performing an extensive pretrans-
plant evaluation reduces transplant-related mortality by
detecting latent infections or unapparent organ dysfunction.
In an attempt to understand the signiﬁcance of the different
components of our pretransplant workup as well as reasons
for delaying or canceling a transplant, we evaluated the
workup of 157 consecutive patients scheduled for allogeneic
HSCT at our center.
METHODS
Patients
Between May 2010 and October 2012, allogeneic transplants were
planned in 100 men and 57 womenwith a median age of 51 years (range, 19
to 70). Patient characteristics are shown in Table 1.edgments on page 1855.
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14.06.029We performed a retrospective chart review of the results of our pre-
transplant workup. Data were collected from electronic and paper charts
and from the institutional database. All patients gave written consent to the
analysis of outcome data at the time of treatment, and the study was
approved by the institutional board of ethics.
At the time of analysis, the pretransplant workup consisted of magnetic
resonance imaging (MRI) of the head; computed tomography (CT) of the
chest and upper abdomen; gynecology, ophthalmology, ears-nose-throat
(ENT), and dental evaluations; pulmonary function tests (PFTs) and echo-
cardiography; and quantitative PCR for cytomegalovirus (CMV) in whole
blood and urine cultures. All patients received a history and thorough
physical examination and disease staging by bone marrow aspirate and
biopsy. Patients with extramedullary disease (mainly those with lympho-
proliferative disorders) additionally received staging by ﬂuorodeoxyglucose
positron emission tomography-CT imaging. Some examinations were
canceled in selected patients because of scheduling issues.
We assessed the results of the pretransplant workup, categorizing
results as “normal or minor ﬁnding” if no abnormalities were found or if
abnormalities were detected that did not lead to further diagnostic or
therapeutic interventions or “major ﬁnding” if results had signiﬁcant con-
sequences such as further testing or therapy. Among major ﬁndings, we
distinguished between those that did not interfere with the transplant
schedule, those that led to delay of the transplant, and those that led to
cancellation of the transplant. In case of a major ﬁnding, we also considered
whether this was incidental or whether the patient had clinical symptoms
or a previous history indicating the patient was at risk for the given ﬁnding.Statistical Analysis
Nonrelapse mortality was deﬁned as death without previous relapse or
progression. The incidence of nonrelapse mortality was calculated using the
cumulative incidence method, and Gray’s test was used to compare among
groups.RESULTS
One hundred twenty-six transplants were performed as
scheduled, whereas 31 transplants were either delayed once
(n ¼ 22) or twice (n ¼ 2) for a median of 21 days (range, 4 to
146) or were canceled altogether (n ¼ 7). The number of
major ﬁndings including those leading to delay or cancella-
tion of transplant are summarized in Table 2 for the
respective examinations. Examinations in which major
ﬁndings led to delaying or canceling a transplant are depic-
ted in Figure 1A. The distribution of incidental and symp-
tomatic diagnoses among major ﬁndings is depicted in
Table 1
Patient Characteristics (N ¼ 157)
Characteristics Value
Median age at transplant, yr (range) 51 (19-70)
Male 100
Female 57
Diagnosis
Acute myeloid leukemia 54
Acute lymphoblastic leukemia 26
Myelodysplastic syndrome 19
Lymphoproliferative disorder 25
Myeloproliferative disease 14
Multiple myeloma 15
Aplastic anemia 4
Planned conditioning intensity
Myeloablative 112
Reduced intensity 45
Donor
Related 70
Unrelated 86
Cord blood 1
Patient origin
Transplant center 54
External center 103
Table 2
Major Findings
Exam (no. patients
evaluated)
Major Finding
No Delay in
Transplant
(n ¼ 126)
Transplant
Delayed
(n ¼ 26)*
Transplant
Canceled
(n ¼ 7)
MRI (n ¼ 150) 4 (3%) 1 (1%) 0 (0%)
CT scan (n ¼ 156) 31 (20%) 4 (3%) 0 (0%)
ENT (n ¼ 153) 18 (12%) 0 (0%) 0 (0%)
Dental evaluation (n ¼ 145) 17 (12%) 2 (1%) 0 (0%)
Gynecology (n ¼ 52) 2 (4%) 0 (0%) 0 (0%)
Ophthalmology (n ¼ 154) 1 (1%) 0 (0%) 0 (0%)
Echocardiography (n ¼ 153) 1 (1%) 0 (0%) 0 (0%)
PFT (n ¼ 153) 5 (3%) 0 (0%) 0 (0%)
CMV PCR (n ¼ 145) 3 (2%) 1 (1%) 0 (0%)
Urine cultures (n ¼ 143) 3 (2%) 0 (0%) 0 (0%)
Clinical evaluation (n ¼ 157) 24 (15%) 7 (4%) 0 (0%)
Disease staging (n ¼ 157) Not
applicable
7 (4%) 6 (4%)
Other Not
applicable
4 (3%) 1 (1%)
Donor issues 3
Toxicity 1
Revision of diagnosis 1
* Transplant was delayed once in 22 patients and twice in 2 patients.
S. Gerull et al. / Biol Blood Marrow Transplant 20 (2014) 1841e1868 1853Figure 1B. The number of major ﬁndings did not differ
between patients referred from other centers and our own
patients (data not shown). None of the patients whose
transplant was delayed for reasons unrelated to the under-
lying disease experienced relapse or progression before be-
ing able to proceed to transplant. The nonreapse mortality at
day 100 for all patients that proceeded to transplant was
11.3%, with 7.7% versus 14.1% for patients with no versus at
least one major ﬁnding, respectively (P ¼ .13).MRI of the Head
Five patients had major ﬁndings in the MRI, 1 of which
resulted in delay of transplant. Therewere 2 cases of clinically
relevant sinusitis, 1 of which was symptomatic; 1 unclear
lesion in the thalamus; 1 case of perineural effusion of both
optic nerves, both of which led to further testing but did not
need speciﬁc therapy; and 1 case of progressive subdural
hematoma, which required surgery and led to a delay of the
transplant. The hematoma was asymptomatic at the time of
the workup but was previously known and had been symp-
tomatic at the timeofﬁrstmanifestation severalweeks before
transplant and was therefore not classiﬁed as incidental.CT of the Chest and Upper Abdomen
Over 20% of CT scans revealed major ﬁndings, of which
almost half were incidental. Most of these were pulmonary
inﬁltrates or nodules (n¼ 29),whereas new liver lesionswere
found in 4 cases and pleural effusions in another 2. All pul-
monary inﬁltrates not previously documented were investi-
gated by bronchoalveolar lavage, and antifungal or
antibacterial therapy was initiated if appropriate (n ¼ 21).
Transplantwas delayed because of previously undocumented
liver lesions (n ¼ 2) or cavitary lesions of the lung (n ¼ 2).Dental Evaluation
Dental evaluation revealed a major ﬁnding in 13% of
patients, with most of these being incidental. Most of these
were severe caries or periodontitis. Of note is the fact that
sanitation of dental foci before transplant was recommended
in 3 patients but not performed because of time constraints.
None of these 3 patients developed active dental infection
post-transplant.ENT Evaluation
A major ﬁnding was diagnosed in 12% of ENT evaluations,
almost all of these being sinus or upper respiratory tract
infections (n¼ 16); however, only 1 ﬁndingwas incidental. In
1 case pretransplant sanitation of chronic sinusitis was rec-
ommended but was not performed because of scheduling
issues. This patient developed a severe fungal sinus infection
3 months post-transplant that required surgical revision.
Gynecology and Ophthalmology Evaluation
Gynecology and ophthalmology evaluation revealed
major ﬁndings in only 4% and 1% of patients, respectively.
Gynecology ﬁndings were bacterial vaginosis treated
with metronidazole in 2 patients, 1 of which was asymp-
tomatic. The major ophthalmologic ﬁnding was idiopathic
asymptomatic bilateral papilledema, which led to further
testing but did not require treatment.
Echocardiography and PFTs
Echocardiography showed only 1 major ﬁnding, which
was a case of previously unknown heart failure, for which
treatment was initiated. Not classiﬁed asmajor ﬁndings were
2 other patients with known heart failure where the echo-
cardiography showed a stable ejection fraction, and therapy
was not adjusted. PFTs showed mild to moderate obstruction
for which inhalation therapy was initiated in 5 patients (3%),
1 of whom had a previous diagnosis of chronic obstructive
lung disease. Abnormal PFTs that did not lead to further
testing or treatment were not classiﬁed as major ﬁndings.
CMV PCR and Urine Culture
Three patients were found by PCR to replicate CMV and
were treated, but transplant was performed as planned. One
patient had a very high CMV load of 586,472 copies/mL and
was symptomatic with CMV colitis with severe diarrhea, and
transplant was delayed for CMV treatment. One further pa-
tient had a low positive CMV PCR that resolved without
treatment and was not classiﬁed as a major ﬁnding. Three
patients received treatment for bacterial urinary tract
infection, which was asymptomatic in 1 patient. Urine cul-
ture was positive in another 9 patients whowere not treated,
but these were not considered as major ﬁndings.
Figure 1. (A) Reasons for delaying or canceling transplant. *Transplant was delayed twice in 2 patients, so there are 26 reasons for delay in 24 transplants.
(B) Frequency and distribution of incidental and symptomatic diagnoses among major ﬁndings in pretransplant evaluation.
S. Gerull et al. / Biol Blood Marrow Transplant 20 (2014) 1841e18681854Clinical Evaluation
History and clinical examination (full physical exam)
showed signs of infection that led to delay of transplant in 4%
of patients. In another 24 patients (16%), clinical evaluation
revealed major ﬁndings that did not result in postponement
of transplant. Although most of these were signs of infection,
mainly upper respiratory tract or gastrointestinal, in 2 of
these 24, conditioning intensity was reduced because of poor
general health.
Disease Staging
In 6 patients, unexpected progressive disease led to
postponement of transplant for reinduction therapy (with 1
patient postponed twice). Transplant was canceled due to
progressive disease in further 6 patients, for a total of 13
postponed or canceled procedures.
Other Events
Transplant was delayed at short notice because of un-
foreseen unavailability of the donor in 3 patients andunexpected toxicity of the conditioning regimen in 1 patient.
In1 patient, transplant was canceled because of spontaneous
recovery of prolonged aplasia after autologous trans-
plantation, so that the initially planned allogeneic transplant
was no longer justiﬁed.DISCUSSION
Wepresent here an analysis of the results of examinations
performed as part of the pretransplant workup before allo-
geneic transplantation at our center. The highest rate of
major ﬁndings was revealed by chest CT and dental and ENT
evaluations, with high rates of incidental major ﬁndings
detected by CT and dental evaluation. All other examinations
revealed only a very low number of major ﬁndings. The most
common reasons for delaying a transplant at short notice
were clinical signs of infection or unexpected progressive
disease. Progressive disease was also the most common
reason for canceling a transplant.
S. Gerull et al. / Biol Blood Marrow Transplant 20 (2014) 1841e1868 1855Although it is common practice to perform an extensive
workup before allogeneic transplantation, very little evi-
dence is available to support the choice of examinations
performed. It seems intuitive to rule out active infection and
ensure sufﬁcient organ function. However, few studies have
assessed the utility of this widely practiced extensive
screening of asymptomatic patients.
Several authors have analyzed the usefulness of ENT
evaluation as well as CT of the sinuses that is practiced in
some centers. Although 1 study in children found patholog-
ical ﬁndings in sinus CT in 67% of patients [5], other studies
uniformly found that signiﬁcant ﬁndings in ENT evaluations
were rare and only found in symptomatic patients [6,7].
There is also conﬂicting data on the possible association of
pretransplant sinus CT and post-transplant development of
sinusitis, with Thompson et al. [8] ﬁnding no correlation in
100 adults, and Billings et al. [9] ﬁnding a signiﬁcant corre-
lation in children. However, these differencesmight inpart be
due to a higher frequency of infections in children.
The question of necessity of dental evaluation pretrans-
plant has also been the subject of several analyses. Although
relatively high rates of pretransplant dental foci ranging up to
44% have been described [6,10], several authors have
compared outcomes of patients with dental foci that were
treatedbefore transplant versus those left untreatedand found
no difference in post-transplant infections or mortality [11,12].
Similar data come from a study in heart transplant patients
[13], keeping in mind that signiﬁcant differences between or-
gan and stem cell transplant limit extrapolation of results. One
studyprospectivelyevaluated aprotocol emphasizingminimal
dental treatment before intensive chemotherapy or transplant
and showed that of 22 patients with severe dental pathology,
only 2 developed infections during chemotherapy, which
promptly resolved with antibiotic treatment [10].
Concerning other pretransplant evaluations, even less data
are available. Only 1 study analyzed the utility of chest CT in
children pretransplant and found a high rate of abnormal CTs
(44%), but only 2% of patients received a new therapy due to a
ﬁnding in chest CT [5]. Another study evaluated pretransplant
MRI of the head in children and concluded that signiﬁcant
ﬁndings requiring therapy in 4.3% of patients justiﬁed
screening MRI [14]. No data have been published on the value
of gynecology or ophthalmology screening before transplant
or on CMV antigenemia screening or urine culture.
For evaluations assessing organ function such as echocar-
diography and PFTs, many studies have analyzed correlations
of pretransplant values with post-transplant complications
[3,15], but none has assessed if screening improved outcome.
However, baseline measurements of organ function can be
crucial to establish reference points for post-transplant
measurements; this is especially true for PFTs [16,17].
In summary, published data on the pretransplant workup
are scarce and ambiguous. When deciding on which com-
ponents to include in the pretransplant workup, many fac-
tors need to be taken into account. Apart from the number of
signiﬁcant ﬁndings, other factors include potential conse-
quences of a missed incidental ﬁnding, burden for the
patient, costs, and value as a baseline measurement. Based
on our analysis of the number of major ﬁndings and inci-
dental, potentially life-threatening ﬁndings in particular, it
seems that CT of the chest and dental evaluation are justiﬁed
irrespective of symptoms. Other components of our exten-
sive workup, including MRI of the head and gynecology and
ophthalmology evaluations, showed a very low rate of major
ﬁndings, suggesting they may be omitted in asymptomaticpatients. However, careful history and clinical examination
are crucial to identify symptomatic or at-risk patients. The
same is true for ENT evaluation, which showed a moderate
rate of major ﬁndings; however, almost all patients were
symptomatic. PFTs, echocardiography, CMV PCR, and urine
culture all yielded no or very few major ﬁndings. Although
PFTs and echocardiography are useful to establish a baseline
for post-transplant assessment, the value of CMV PCR and
urine culture is less clear.
Another aspect of our analysis is information on delayed
or canceled transplants. In addition to several transplants
delayed because of acute infection, progressive disease was
the most common reason for not continuing with transplant
as planned. Less frequently, transplants were delayed
because of ﬁndings on CTof the chest or in dental evaluation.
Because of logistic reasons, the pretransplant workup in our
center is performed immediately before start of condition-
ing. This circumstancemost likely had a signiﬁcant inﬂuence,
particularly on the number of delayed transplants, because a
workup performed several weeks before transplant would
leave sufﬁcient time to perform any necessary interventions
without delaying the transplant. Although our practice has
certain advantages, rescheduling a transplant at short notice
has signiﬁcant consequences for transplant coordination and
the donor. Our results suggest that sufﬁcient time between
the workup and planned start of conditioning is crucial to
deal with unexpected ﬁndings. Furthermore, in light of the
fact that dental and ENT sanitation was recommended in
several patients but not performed because of time con-
straints, dental and ENT evaluations in particular should be
performed with sufﬁcient lead time.
Our study has several limitations. Because of the retro-
spective nature, we could not account for patients whomight
have had an informal workup and were not referred for
transplant because of eligibility concerns. Furthermore, we
could only assess the number of major symptomatic and
incidental ﬁndings and could not correlate major ﬁndings
with outcome or determine how pretransplant ﬁndings
might have inﬂuenced post-transplant decisions. Most
importantly, we can only speculate on potential conse-
quences of omitting certain components of the workup.
Prospective studies are necessary to study whether such an
approach is safe. Although our results seem to encourage a
more restrictive workup, a single missed major ﬁnding could
potentially have fatal consequences. Keeping that in mind,
unwarranted large-scale screening also harbors potential
risks, including complications of diagnostic procedures and
unnecessary delay of transplant. However, our data clearly
indicate that prospective evaluation of a less-extensive and
symptom-guided workup is warranted.ACKNOWLEDGMENT
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Diarrhea, abdominal pain, and fever are common among patients undergoing hematopoietic cell trans-
plantation (HCT), but such symptoms are also typical with foodborne infections. The burden of disease caused
by foodborne infections in patients undergoing HCT is unknown. We sought to describe bacterial foodborne
infection incidence after transplantation within a single-center population of HCT recipients. All HCT
recipients who underwent transplantation from 2001 through 2011 at the Fred Hutchinson Cancer Research
Center in Seattle, Washington were followed for 1 year after transplantation. Data were collected retro-
spectively using center databases, which include information from transplantation, on-site examinations,
outside records, and collected laboratory data. Patients were considered to have a bacterial foodborne
infection if Campylobacter jejuni/coli, Listeria monocytogenes, E. coli O157:H7, Salmonella species, Shigella
species, Vibrio species, or Yersinia species were isolated in culture within 1 year after transplantation. Non-
foodborne infections with these agents and patients with pre-existing bacterial foodborne infection (within
30 days of transplantation) were excluded from analyses. A total of 12 of 4069 (.3%) patients developed a
bacterial foodborne infection within 1 year after transplantation. Patients with infections had a median age at
transplantation of 50.5 years (interquartile range [IQR], 35 to 57), and the majority were adults 18 years of
age (9 of 12 [75%]), male gender (8 of 12 [67%]) and had allogeneic transplantation (8 of 12 [67%]). Infectious
episodes occurred at an incidence rate of 1.0 per 100,000 patient-days (95% conﬁdence interval, .5 to 1.7) and
at a median of 50.5 days after transplantation (IQR, 26 to 58.5). The most frequent pathogen detected was
C. jejuni/coli (5 of 12 [42%]) followed by Yersinia (3 of 12 [25%]), although Salmonella (2 of 12 [17%]) and Listeria
(2 of 12 [17%]) showed equal frequencies; no cases of Shigella, Vibrio, or E. coli O157:H7 were detected. Most
patients were diagnosed via stool (8 of 12 [67%]), fewer through blood (2 of 12 [17%]), 1 via both stool and
blood simultaneously, and 1 through urine. Mortality due to bacterial foodborne infection was not observed
during follow-up. Our large single-center study indicates that common bacterial foodborne infections were a
rare complication after HCT, and the few cases that did occur resolved without complications. These data
provide important baseline incidence for future studies evaluating dietary interventions for HCT patients.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Immunocompromised patients are known to be vul-
nerable to foodborne pathogens [1-6]. Hematopoietic cell
transplantation (HCT) recipients have multiple factors that
increase risk for foodborne infections, including profound
deﬁcits in innate and adaptive immunity and disruption of
gastrointestinal mucosa from transplantation-associated
